Sage Therapeutics is this week’s best biotech stock. Sage has several data points coming out soon that could give the stock a big lift.

SAGE-718 for huntington’s disease. Phase 1 biomarker data due July 2019 with Huntington’s Disease Phase 1 cohort data due 2H 2019.

SAGE-324 for essential tremors. Phase 1 MAD data due July 2019. Top-line data due 2H 2019.

SAGE-217 – ARCHWAY for Bipolar depression. Phase 2 Part A data due July 2019.

“We started 2019 with positive data from a Phase 3 clinical trial of our lead oral compound SAGE-217 in postpartum depression and this was quickly followed by the FDA approval of ZULRESSO in PPD,” said Jeff Jonas, M.D., chief executive officer at Sage. “It was gratifying that our first drug approval generated extensive media coverage of a disorder that for too long has been shrouded by stigma and shame. We anticipate additional momentum in our development efforts during the remainder of the year across our three franchises in depression, neurology and neuropsychiatry and believe the depth and breadth of our novel portfolio of compounds in these areas is unrivaled in the industry. We are confident in our potential to create a paradigm shift in the way brain health is thought about and treated.”

Large players volume looks nice and stock has been in a continuation pattern.

Sage is NOT being added to the long-term buy and hold GST Portfolio. This is a high risk, high reward play only for those who like to speculate.

Disclosure: I do not hold any position in Sage stock.